Lanthanum carbonate (Shire).

Shire Pharmaceuticals Group plc, under exclusive license from AnorMED Inc (a subsidiary of Johnson Matthey), is developing lanthanum carbonate, a phosphate-binding lanthanum salt, for the potential treatment of hyperphosphatemia in dialysis patients. It is currently in pre-registration in the US, Canada and Western Europe, and earlier stage clinical trials are ongoing in Japan.